A Phase I/II Clinical Trial of Hematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome

Trial Profile

A Phase I/II Clinical Trial of Hematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Jan 2018

At a glance

  • Drugs GSK 2696275 (Primary)
  • Indications Wiskott-Aldrich syndrome
  • Focus Adverse reactions; First in man; Pharmacodynamics; Therapeutic Use
  • Acronyms TIGET-WAS
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 22 Jan 2018 Planned primary completion date changed from 11 Mar 2019 to 11 Sep 2018.
    • 19 Jan 2018 Planned primary completion date changed from 11 Sep 2018 to 11 Mar 2019.
    • 15 Jan 2018 Planned End Date changed from 31 Mar 2023 to 11 Sep 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top